Several brokerages have updated their recommendations and price targets on shares of Intellia Therapeutics (NASDAQ: NTLA) in the last few weeks: 2/24/2023 – Intellia Therapeutics was upgraded by analysts at StockNews.com to a 'sell' rating. 2/24/2023 – Intellia Therapeutics had its price target lowered by analysts at Raymond James from $124.00 to $94.00. They now have an 'outperform' rating on the stock. 2/24/2023 – Intellia Therapeutics had its price target lowered by analysts at Oppenheimer Holdings Inc.

https://www.dailypolitical.com/2023/03/06/intellia-therapeutics-ntla-research-analysts-recent-ratings-changes.html

#dailypolitical